Compare Cardinal Health Inc (CAH) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Icl Group Ltd — how do they compare? Cardinal Health Inc trades at $228.59 (market cap $53.89B), while Icl Group Ltd trades at $5.01 (market cap $6.49B). The key difference: Cardinal Health Inc is far larger — about 8.3× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| CAH | ICL | |
|---|---|---|
Market Cap | $53.89B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $239.71 | $7.03 |
52-Week Low | $146.04 | $4.80 |
Enterprise Value | $58.87B | $9.06B |
Dividend Yield | 0.89% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
ICL trades at $4.93, up 1.65% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of $0.11, beating expectations, and maintains a dividend of $0.05. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation ratios like P/E of 23.48 and P/S of 0.86 suggest moderate pricing. Recent news highlights a $800M senior notes offering completed in June 2026.
Outlook is mixed: earnings beats and dividend yield offer support, but declining profit margins and bearish analyst consensus (100% hold) indicate caution. Key risks include raw material costs and forex headwinds, with institutional sentiment leaning neutral amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
